Rochem Methotrexate Rochem Methotrexate

X

Find Radio Compass News for Methotrexate

PharmaCompass
Related ProductsRelated Products
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

JDMFs Filed

JDMFs Filed

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

0

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

JP

Other Listed Suppliers

SERVICES

0

left grey arrow
right gray arrow
  • INJECTABLE;INJECTION - EQ 100MG BASE/VIAL
  • INJECTABLE;INJECTION - EQ 1GM BASE/VIAL
  • INJECTABLE;INJECTION - EQ 1GM BASE/40ML (EQ 25MG BASE/ML)
  • INJECTABLE;INJECTION - EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)
  • INJECTABLE;INJECTION - EQ 2.5MG BASE/ML
  • INJECTABLE;INJECTION - EQ 20MG BASE/VIAL
  • INJECTABLE;INJECTION - EQ 20MG BASE/2ML (EQ 10MG BASE/ML)
  • INJECTABLE;INJECTION - EQ 25MG BASE/ML
  • INJECTABLE;INJECTION - EQ 500MG BASE/20ML (EQ 25MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
  • INJECTABLE;INJECTION - EQ 50MG BASE/VIAL
  • INJECTABLE;INJECTION - EQ 50MG BASE/2ML (EQ 25MG BASE/ML)
  • SOLUTION;SUBCUTANEOUS - 10MG/0.4ML (10MG/0.4ML)
  • SOLUTION;SUBCUTANEOUS - 12.5MG/0.5ML (12.5MG/0.5ML)
  • SOLUTION;SUBCUTANEOUS - 15MG/0.6ML (15MG/0.6ML)
  • SOLUTION;SUBCUTANEOUS - 17.5MG/0.7ML (17.5MG/0.7ML)
  • SOLUTION;SUBCUTANEOUS - 20MG/0.8ML (20MG/0.8ML)
  • SOLUTION;SUBCUTANEOUS - 22.5MG/ML (22.5MG/ML)
  • SOLUTION;SUBCUTANEOUS - 25MG/1ML (25MG/1ML)
  • SOLUTION;SUBCUTANEOUS - 7.5MG/0.3ML (7.5MG/0.3ML)
  • TABLET;ORAL - EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

https://www.prnewswire.com/news-releases/shorla-oncology--eversana-announce-us-commercial-launch-of-fda-approved-jylamvo-the-first-and-only-oral-methotrexate-solution-approved-in-the-us-for-adults-302018960.html

PR NEWSWIRE
19 Dec 2023

https://endpts.com/sandoz-opens-two-new-facilities-gates-foundation-funds-needle-less-vaccines-novartis-expands-japanese-site/

ENDPTS
16 Nov 2023

https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-november-1-2023-13847.pdf

FDA
01 Nov 2023

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213362

FDA
07 Aug 2023

https://www.onclive.com/view/nccn-issues-guideline-update-on-the-use-of-high-dose-methotrexate-glucarpidase-in-all-b-cell-lymphoma

ONCLIVE
07 Jul 2023

https://www.businesswire.com/news/home/20230706657904/en

BUSINESSWIRE
06 Jul 2023

https://www.businesswire.com/news/home/20230629018435/en

BUSINESSWIRE
29 Jun 2023

https://www.businesswire.com/news/home/20230621069126/en

BUSINESSWIRE
21 Jun 2023

https://www.reuters.com/business/healthcare-pharmaceuticals/us-seeks-new-suppliers-highly-used-cancer-drug-methotrexate-short-supply-2023-06-09/

REUTERS
09 Jun 2023

https://www.accessdata.fda.gov/cms_ia/importalert_189.html

FDA
06 Jun 2023

https://timesofindia.indiatimes.com/city/hyderabad/life-threatening-bacteria-found-in-hyderabad-companys-cancer-drug-who/articleshow/99043682.cms?from=mdr

TIMES OF INDIA
28 Mar 2023

https://www.businesswire.com/news/home/20230301005873/en

BUSINESSWIRE
02 Mar 2023

https://health.economictimes.indiatimes.com/news/pharma/methotrexate-use-is-linked-to-an-increased-risk-of-skin-cancer-study/97737152

HEALTH ET
08 Feb 2023

https://www.fiercebiotech.com/biotech/regimmune-touts-compelling-phase-2-data-stem-call-transplant-patients-readies-phase-3

James Waldron FIERCEBIOTECH
20 Dec 2022

https://www.businesswire.com/news/home/20221108005040/en

BUSINESSWIRE
08 Nov 2022

https://www.businesswire.com/news/home/20221105005026/en

BUSINESSWIRE
05 Nov 2022

https://www.businesswire.com/news/home/20221005005669/en

BUSINESSWIRE
05 Oct 2022

https://www.biospectrumasia.com/news/25/21116/japan-approves-subcutaneous-injection-formulation-for-rheumatoid-arthritis.html

BIOSPECTRUMASIA
28 Sep 2022

https://www.businesswire.com/news/home/20220801005815/en

BUSINESSWIRE
03 Aug 2022

https://www.fiercepharma.com/pharma/horizons-krystexxa-gets-new-combo-indication-methotrexate-breathes-new-life-drug

Zoey Becker FIERCEPHARMA
09 Jul 2022

https://www.businesswire.com/news/home/20220601005408/en

BUSINESSWIRE
01 Jun 2022

https://www.globenewswire.com/news-release/2022/03/31/2413910/0/en/Assertio-Holdings-Inc-Partners-with-BlinkRx-to-Support-Healthcare-Providers-and-Patients-Utilizing-Otrexup-methotrexate-with-a-Unique-Patient-Access-Solution.html

GLOBENEWSWIRE
31 Mar 2022

https://www.businesswire.com/news/home/20220307005987/en

BUSINESSWIRE
08 Mar 2022

https://www.businesswire.com/news/home/20220307005264/en

BUSINESSWIRE
07 Mar 2022

https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-2-2022-1643778781.pdf

FDA
02 Feb 2022

https://www.businesswire.com/news/home/20220110005332/en

BUSINESSWIRE
10 Jan 2022

https://www.businesswire.com/news/home/20220103005519/en

BUSINESSWIRE
04 Jan 2022

https://www.prnewswire.com/news-releases/abbvie-expands-immunology-portfolio-in-the-european-union-with-the-european-commission-approval-of-skyrizi-risankizumab-for-the-treatment-of-adults-with-active-psoriatic-arthritis-301426412.html

PRNEWSWIRE
17 Nov 2021

http://www.pharmafile.com/news/590481/nice-approves-treatment-rheumatoid-arthritis

PHARMAFILE
12 Oct 2021

https://www.firstwordpharma.com/node/1836757?tsid=4

FIRSTWORLDPHARMA
10 Jun 2021

https://www.nice.org.uk/news/article/nice-recommends-several-treatment-options-to-help-thousands-with-moderate-rheumatoid-arthritis#:~:text=NICE%20has%20today%20(10th,for%20use%20within%20the%20NHS.

NICE
10 Jun 2021

https://www.globenewswire.com/news-release/2021/06/07/2242674/0/en/Equillium-to-Collaborate-with-Oxford-University-and-Kennedy-Institute-of-Rheumatology-to-Investigate-Role-of-the-CD6-ALCAM-Pathway-and-Itolizumab-in-Rheumatic-Diseases.html

GLOBENEWSWIRE
07 Jun 2021

https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-20-2021-1611205836.pdf

FDA
20 Jan 2021

https://www.raps.org/news-and-articles/news-articles/2020/12/azurity-garners-opdp-untitled-letter-for-marketing

Kari Oakes RAPS
04 Dec 2020

https://www.prnewswire.com/news-releases/initial-study-results-show-feasibility-of-outpatient-methotrexate-administration-with-planned-use-voraxaze-glucarpidase-during-covid-19-pandemic-301171687.html

PRNEWSWIRE
12 Nov 2020

https://acrabstracts.org/abstract/the-association-of-methotrexate-sulfasalazine-and-hydroxychloroquine-use-with-incident-fractures-in-postmenopausal-women-with-rheumatoid-arthritis-findings-from-the-womens-health-initiative/

ACRABSTRACTS
09 Nov 2020

https://www.businesswire.com/news/home/20201029005178/en

BUSINESSWIRE
30 Oct 2020

https://www.gov.uk/drug-safety-update/methotrexate-once-weekly-for-autoimmune-diseases-new-measures-to-reduce-risk-of-fatal-overdose-due-to-inadvertent-daily-instead-of-weekly-dosing

GOV.UK
23 Sep 2020

https://www.businesswire.com/news/home/20200916005194/en/MIRROR-Open-Label-Trial-Data-Published-in-Journal-of-Rheumatology-Show-79-Percent-of-Patients-Achieved-a-Complete-Response-Using-KRYSTEXXA%C2%AE-pegloticase-injection-with-Methotrexate

BUSINESSWIRE
16 Sep 2020

https://www.newswire.ca/news-releases/health-canada-approves-tremfya-r-guselkumab-injection-a-first-in-class-selective-interleukin-il-23-inhibitor-for-active-psoriatic-arthritis-822702384.html

NEWSWIRE
10 Sep 2020

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214121

FDA
27 Aug 2020

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214121

FDA
27 Aug 2020

https://www.hikma.com/newsroom/article-i2953-hikma-launches-methotrexate-injection-usp-and-methotrexate-for-injection-usp/

PRESS RELEASE
24 Jul 2020

https://www.biospace.com/article/releases/target-enrollment-reached-in-mirror-randomized-controlled-trial-evaluating-krystexxa-pegloticase-injection-co-prescribed-with-methotrexate-as-an-immunomodulator-to-enhance-response-rates-for-people-living-with-uncontrolled-gout/

BIOSPACE
22 Jul 2020

https://www.fresenius-kabi.com/news/fresenius-kabi-enters-marketing-agreement-for-biosimilar-product

FRESENIUS-KABI
28 May 2020

https://www.prnewswire.com/news-releases/study-underway-to-examine-the-planned-use-of-voraxaze-with-methotrexate-in-cns-lymphoma-301045797.html

PR NEWSWIR
23 Apr 2020

https://markets.businessinsider.com/news/stocks/can-fite-completes-50-patient-enrollment-in-phase-iii-rheumatoid-arthritis-study-implements-interim-analysis-1028867348

BUSINESSINSIDER
03 Feb 2020

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210454

FDA
01 Feb 2020

https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-receives-fda-approval-for-reditrex-product-line-300966976.html

PR NEWSWIRE
02 Dec 2019

http://www.pharmabiz.com/NewsDetails.aspx?aid=118135&sid=2

PHARMABIZ
13 Sep 2019
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY